Partner Therapeutics Announces Receipt of FDA Commissioner's National Priority Voucher for BIZENGRI® (Zenocutuzumab-zbco) in NRG1 Fusion-Positive Cholangiocarcinoma

Voucher Recognizes High Unmet Medical Need in Ultra-Rare, Molecularly Defined Cholangiocarcinoma LEXINGTON, Mass., May 6, 2026 /PRNewswire/ -- Partner Therapeutics, Inc. (PTx), a private, fully integrated biotechnology company, today announced that the U.S. Food and Drug Administration...